Rovelizumab | Interleukin Related interleukin-related.com

Product Name :
Rovelizumab

Search keywords :
Rovelizumab

drugId :
null

Target Vo:
Integrin alpha-L/beta-2 (LFA-1)

Target Vo Short Name :
ITGAL&ITGB2

Moa_Name:
Integrin alpha-L/beta-2 (LFA-1) antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Icos Corporation

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Respiratory Distress Syndrome, Adult

Termination Status :
Phase 3 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Casirivimab Cancer
Tisotumab Technical Information
NDRG1 Antibody: NDRG1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to NDRG1. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts